ADC Therapeutics
ADCT
56 hedge funds and large institutions have $97.5M invested in ADC Therapeutics in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 13 closing their positions.
7% more capital invested
Capital invested by funds: $90.9M → $97.5M (+$6.65M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.55% less ownership
Funds ownership: 57.8% → 56.25% (-1.6%)
5% less funds holding
Funds holding: 59 → 56 (-3)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
80% less call options, than puts
Call options by funds: $5K | Put options by funds: $25K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$5.23M |
| 2 |
SCM
Sio Capital Management
New York
|
+$4.18M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$1.09M |
| 4 |
Morgan Stanley
New York
|
+$483K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$466K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.27M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.92M |
| 3 |
Goldman Sachs
New York
|
-$2.73M |
| 4 |
Millennium Management
New York
|
-$830K |
| 5 |
JP Morgan Chase
New York
|
-$746K |
ADCT Hedge Fund Activity: Q2 2023 in Review
56 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2023, worth a combined $97.5M — up 7.3% from $90.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ADCT and 10 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 14 added.
The largest buyer was Prosight Management, adding an estimated $5.23M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $3.27M sold.
- 56 institutional investors held ADC Therapeutics (ADCT) as of Q2 2023, down from 59 in Q1 2023.
- Funds reported $97.5M of ADC Therapeutics stock for Q2 2023, up 7.3% quarter-over-quarter.
- 10 funds opened new ADC Therapeutics positions in Q2 2023 and 13 closed out, a net change of -3 holders.
- The largest ADC Therapeutics buyer in Q2 2023 was Prosight Management, an estimated $5.23M added.
- The largest ADC Therapeutics seller in Q2 2023 was Eventide Asset Management, an estimated $3.27M sold.
Based on aggregated 13F filings for Q2 2023.